-
1
-
-
0029659028
-
Olanzapine: A new atypical antipsychotic drug
-
Feb
-
Meltzer HY, Fibiger HC. Olanzapine: a new atypical antipsychotic drug. Neuropsychopharmacology 1996 Feb; 14: 83-5
-
(1996)
Neuropsychopharmacology
, vol.14
, pp. 83-85
-
-
Meltzer, H.Y.1
Fibiger, H.C.2
-
2
-
-
0030062260
-
Radioreceptor binding profile of the atypical antipsychotic olanzapine
-
Feb
-
Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996 Feb; 14: 87-96
-
(1996)
Neuropsychopharmacology
, vol.14
, pp. 87-96
-
-
Bymaster, F.P.1
Calligaro, D.O.2
Falcone, J.F.3
-
3
-
-
0029930927
-
Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
-
Mar
-
Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996 Mar; 124: 57-73
-
(1996)
Psychopharmacology
, vol.124
, pp. 57-73
-
-
Schotte, A.1
Janssen, P.F.M.2
Gommeren, W.3
-
4
-
-
0028261434
-
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
-
Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268 (3): 1403-10
-
(1994)
J Pharmacol Exp Ther
, vol.268
, Issue.3
, pp. 1403-1410
-
-
Roth, B.L.1
Craigo, S.C.2
Choudhary, M.S.3
-
5
-
-
0029954801
-
Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review
-
May
-
Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 1996 May; 168 Suppl. 29: 23-31
-
(1996)
Br J Psychiatry
, vol.168
, Issue.29 SUPPL.
, pp. 23-31
-
-
Meltzer, H.Y.1
-
6
-
-
0028990758
-
4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs
-
Aug
-
4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 1995 Aug; 120 (13): 365-8
-
(1995)
Psychopharmacology
, vol.120
, Issue.13
, pp. 365-368
-
-
Roth, B.L.1
Tandra, S.2
Burgess, L.H.3
-
8
-
-
0028965905
-
Distribution of putative D4 dopamine receptors in postmorten striatum from patients with schizophrenia
-
Murray AM, Hyde TN, Knable MB, et al. Distribution of putative D4 dopamine receptors in postmorten striatum from patients with schizophrenia. J Neurosci 1995; 15: 2186-91
-
(1995)
J Neurosci
, vol.15
, pp. 2186-2191
-
-
Murray, A.M.1
Hyde, T.N.2
Knable, M.B.3
-
9
-
-
0027485692
-
Dopamine D4 receptors elevated in schizophrenia
-
Seeman P, Guan H-C, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441-5
-
(1993)
Nature
, vol.365
, pp. 441-445
-
-
Seeman, P.1
Guan, H.-C.2
Van Tol, H.H.M.3
-
11
-
-
0030048254
-
Effects of olanzapine on regional C-Fos expression in rat forebrain
-
Feb
-
Robertson GS, Fibiger HC. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 1996 Feb; 14: 105-10
-
(1996)
Neuropsychopharmacology
, vol.14
, pp. 105-110
-
-
Robertson, G.S.1
Fibiger, H.C.2
-
14
-
-
0029927536
-
Mechanisms of action of atypical antipsychotic drugs: A critical analysis
-
Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996; 124: 2-34
-
(1996)
Psychopharmacology
, vol.124
, pp. 2-34
-
-
Kinon, B.J.1
Lieberman, J.A.2
-
15
-
-
0030040463
-
Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons
-
Feb
-
Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996 Feb; 14: 97-104
-
(1996)
Neuropsychopharmacology
, vol.14
, pp. 97-104
-
-
Stockton, M.E.1
Rasmussen, K.2
-
16
-
-
0029117583
-
Differential effects of repealed administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat
-
Aug 15
-
Skarsfeldt T. Differential effects of repealed administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995 Aug 15; 281: 289-94
-
(1995)
Eur J Pharmacol
, vol.281
, pp. 289-294
-
-
Skarsfeldt, T.1
-
17
-
-
0030012214
-
Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells
-
Mar
-
Stockton ME, Rasmussen K. Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology 1996 Mar; 124: 50-6
-
(1996)
Psychopharmacology
, vol.124
, pp. 50-56
-
-
Stockton, M.E.1
Rasmussen, K.2
-
19
-
-
0029030343
-
Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors
-
Jul
-
Corbett R, Camacho F, Woods AT, et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 1995 Jul; 120 (1): 67-74
-
(1995)
Psychopharmacology
, vol.120
, Issue.1
, pp. 67-74
-
-
Corbett, R.1
Camacho, F.2
Woods, A.T.3
-
20
-
-
0026757929
-
The behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent
-
Aug
-
Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 1992 Aug; 262: 545-51
-
(1992)
J Pharmacol Exp Ther
, vol.262
, pp. 545-551
-
-
Moore, N.A.1
Tye, N.C.2
Axton, M.S.3
-
22
-
-
0029098028
-
Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability
-
Jul
-
Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 1995 Jul; 120(2): 128-33
-
(1995)
Psychopharmacology
, vol.120
, Issue.2
, pp. 128-133
-
-
Hoffman, D.C.1
Donovan, H.2
-
23
-
-
0343595691
-
Restoration of the amphetamine-disrupted latent inhibition by olanzapine in the rat
-
Gosselin O, Majchrzak M, Oberling P, et al. Restoration of the amphetamine-disrupted latent inhibition by olanzapine in the rat. Behav Pharmacol 1996; 7 Suppl. 1: 46
-
(1996)
Behav Pharmacol
, vol.7
, Issue.1 SUPPL.
, pp. 46
-
-
Gosselin, O.1
Majchrzak, M.2
Oberling, P.3
-
24
-
-
0029563620
-
Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
-
Nov
-
Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995 Nov; 122 (2): 198-201
-
(1995)
Psychopharmacology
, vol.122
, Issue.2
, pp. 198-201
-
-
Bakshi, V.P.1
Geyer, M.A.2
-
25
-
-
0029928183
-
Similarity of clozapine's and olanzapine's acute effects on rats' lapping behavior
-
Feb
-
Das S, Fowler SC. Similarity of clozapine's and olanzapine's acute effects on rats' lapping behavior. Psychopharmacology 1996 Feb; 123 (4): 374-8
-
(1996)
Psychopharmacology
, vol.123
, Issue.4
, pp. 374-378
-
-
Das, S.1
Fowler, S.C.2
-
26
-
-
0029073180
-
Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons
-
May
-
Benvenga MJ, Leander JD. Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology 1995 May; 119: 133-8
-
(1995)
Psychopharmacology
, vol.119
, pp. 133-138
-
-
Benvenga, M.J.1
Leander, J.D.2
-
27
-
-
0028301260
-
Effecls of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule
-
Apr
-
Moore NA, Rees G, Sanger G, et al. Effecls of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994 Apr; 5: 196-202
-
(1994)
Behav Pharmacol
, vol.5
, pp. 196-202
-
-
Moore, N.A.1
Rees, G.2
Sanger, G.3
-
28
-
-
0028966444
-
Olanzapine moderately increases conflict responding but does not produce a benzodiazepine-like cue in rat
-
Mar
-
Nanry KP, Pollard GT, Howard JL. Olanzapine moderately increases conflict responding but does not produce a benzodiazepine-like cue in rat. Drug Dev Res 1995 Mar; 34: 317-9
-
(1995)
Drug Dev Res
, vol.34
, pp. 317-319
-
-
Nanry, K.P.1
Pollard, G.T.2
Howard, J.L.3
-
29
-
-
0029020015
-
The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: Effect of risperidone, prothipendyl. ORG 5222, sertindole and olanzapine
-
Jun
-
Cools AR, Prinssen EPM, Ellenbroek BA. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl. ORG 5222, sertindole and olanzapine Psychopharmacology 1995 Jun; 119: 428-39
-
(1995)
Psychopharmacology
, vol.119
, pp. 428-439
-
-
Cools, A.R.1
Prinssen, E.P.M.2
Ellenbroek, B.A.3
-
30
-
-
0030007496
-
Differential effect of antipsychotics on place navigation of rats in the Morris water maze: A comparative study between novel and reference antipsychotics
-
Mar
-
Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze: a comparative study between novel and reference antipsychotics. Psychopharmacology 1996 Mar; 124: 126-33
-
(1996)
Psychopharmacology
, vol.124
, pp. 126-133
-
-
Skarsfeldt, T.1
-
31
-
-
0030065502
-
Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
-
Feb
-
Beasley Jr CM, Tollefson G, Tran P. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996 Feb; 14: 111-23
-
(1996)
Neuropsychopharmacology
, vol.14
, pp. 111-123
-
-
Beasley Jr., C.M.1
Tollefson, G.2
Tran, P.3
-
34
-
-
0026651080
-
Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY 170053), an antipsychotic drug candidate
-
Jul
-
Fuller RW, Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY 170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 1992 Jul; 77: 87-93
-
(1992)
Res Commun Chem Pathol Pharmacol
, vol.77
, pp. 87-93
-
-
Fuller, R.W.1
Snoddy, H.D.2
-
35
-
-
0013684420
-
The disposition of olanzapine in healthy volunteers
-
abstract no. 120
-
Boyd D, Obermeyer BD, Nyhart Jr EH, et al. The disposition of olanzapine in healthy volunteers [abstract no. 120]. Pharmacologist 1993; 35 (3): 176
-
(1993)
Pharmacologist
, vol.35
, Issue.3
, pp. 176
-
-
Boyd, D.1
Obermeyer, B.D.2
Nyhart Jr., E.H.3
-
36
-
-
0001345614
-
Pharmacokinetics of olanzapine in elderly and young
-
Sep
-
Bergstrom RF, Callaghan JT, Cerimele BJ, et al. Pharmacokinetics of olanzapine in elderly and young [abstract]. Pharm Res 1995 Sep; 12 Suppl.: S358
-
(1995)
Pharm Res
, vol.12
, Issue.SUPPL.
-
-
Bergstrom, R.F.1
Callaghan, J.T.2
Cerimele, B.J.3
-
37
-
-
0000960701
-
Combined population pharmacokinetic analysis of olanzapine in healthy volunteers
-
Sep
-
Patel BR, Nyhart Jr EH, Callaghan JT, et al. Combined population pharmacokinetic analysis of olanzapine in healthy volunteers [abstract]. Pharm Res 1995 Sep; 12 Suppl.: 360
-
(1995)
Pharm Res
, vol.12
, Issue.SUPPL.
, pp. 360
-
-
Patel, B.R.1
Nyhart Jr., E.H.2
Callaghan, J.T.3
-
39
-
-
0030077735
-
Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine
-
Feb
-
Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996 Feb; 276: 658-66
-
(1996)
J Pharmacol Exp Ther
, vol.276
, pp. 658-666
-
-
Ring, B.J.1
Catlow, J.2
Lindsay, T.J.3
-
40
-
-
0029983702
-
In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A
-
Mar
-
Ring BJ, Binkley SN, Vandenbranden M, et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996 Mar; 41: 181-6
-
(1996)
Br J Clin Pharmacol
, vol.41
, pp. 181-186
-
-
Ring, B.J.1
Binkley, S.N.2
Vandenbranden, M.3
-
41
-
-
0001440282
-
Interaction between olanzapine and lithium in healthy male volunteers
-
abstract no. 486
-
Demolle D, Onkelinx C, Müller-Oerlinghausen B. Interaction between olanzapine and lithium in healthy male volunteers [abstract no. 486]. Therapie 1995; 50 Suppl.
-
(1995)
Therapie
, vol.50
, Issue.SUPPL.
-
-
Demolle, D.1
Onkelinx, C.2
Müller-Oerlinghausen, B.3
-
42
-
-
0029052541
-
The aims of antipsychotic medication: What are they and are they being achieved?
-
Awad AG, Voruganti LNP, Heslegrave RJ. The aims of antipsychotic medication: what are they and are they being achieved? CNS Drugs 1995; 4 (1): 8-16
-
(1995)
CNS Drugs
, vol.4
, Issue.1
, pp. 8-16
-
-
Awad, A.G.1
Voruganti, L.N.P.2
Heslegrave, R.J.3
-
43
-
-
0003412410
-
-
Bethesda, MD, US Department of Health, Education and Welfare
-
Guy W. ECDEU Assessment manual for psychopharmacology, revised version. Bethesda, MD, US Department of Health, Education and Welfare, 1976
-
(1976)
ECDEU Assessment Manual for Psychopharmacology, Revised Version
-
-
Guy, W.1
-
45
-
-
0003472161
-
-
Multi-Health Systems, North Tonawanda, New York
-
Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. Multi-Health Systems, North Tonawanda, New York, 1996
-
(1996)
Positive and Negative Syndrome Scale (PANSS) Manual
-
-
Kay, S.R.1
Opler, L.A.2
Fiszbein, A.3
-
46
-
-
0019945902
-
Negative symptoms in schizophrenia
-
Andreason NC. Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982; 39: 784-8
-
(1982)
Arch Gen Psychiatry
, vol.39
, pp. 784-788
-
-
Andreason, N.C.1
-
47
-
-
0029930337
-
Olanzapine versus placebo: Results of a double-blind, fixed dose olanzapine trial
-
Mar
-
Beasley Jr CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed dose olanzapine trial. Psychopharmacology 1996 Mar; 124: 159-67
-
(1996)
Psychopharmacology
, vol.124
, pp. 159-167
-
-
Beasley Jr., C.M.1
Sanger, T.2
Satterlee, W.3
-
50
-
-
0028790556
-
First clinical experience with olanzapine (LY 170053): Results of an open-label safety and dose-ranging study in patients with schizophrenia
-
Nov
-
Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol 1995 Nov; 10: 239-44
-
(1995)
Int Clin Psychopharmacol
, vol.10
, pp. 239-244
-
-
Baldwin, D.S.1
Montgomery, S.A.2
-
55
-
-
8044235047
-
Quality of life outcomes of olanzapine, a new atypical antipsychotic agent
-
Mar, Crans-Montana, Switzerland
-
Martin C, Genduso L, Revicki D, et al. Quality of life outcomes of olanzapine, a new atypical antipsychotic agent (abstract). Presented at the Winter Workshop on Schizophrenia; 1996 Mar, Crans-Montana, Switzerland
-
(1996)
Winter Workshop on Schizophrenia
-
-
Martin, C.1
Genduso, L.2
Revicki, D.3
-
56
-
-
0347399800
-
Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and related psychotic disorders
-
New York, USA
-
Revicki D, Genduso LA, Hamilton SL, et al. Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and related psychotic disorders (abstract). Presented at the American Psychiatry Association Annual Meeting; 1996, New York, USA
-
(1996)
American Psychiatry Association Annual Meeting
-
-
Revicki, D.1
Genduso, L.A.2
Hamilton, S.L.3
-
57
-
-
8044225386
-
Quality of life and olanzapine treatment in schizophrenia: Results of an international double-blind randomized clinical trial
-
Mar, Crans-Montana, Switzerland
-
Martin C, Genduso L, Revicki D, et al. Quality of life and olanzapine treatment in schizophrenia: results of an international double-blind randomized clinical trial (abstract). Presented at the Winter Workshop on Schizophrenia; 1996 Mar, Crans-Montana, Switzerland
-
(1996)
Winter Workshop on Schizophrenia
-
-
Martin, C.1
Genduso, L.2
Revicki, D.3
-
58
-
-
8044249086
-
Safety overview of olanzapine
-
Aug, Madrid, Spain
-
Beasley C, Tollefson G, Wood A, et al. Safety overview of olanzapine (abstract). Presented at the X World Congress of Psychiatry; 1996 Aug, Madrid, Spain
-
(1996)
X World Congress of Psychiatry
-
-
Beasley, C.1
Tollefson, G.2
Wood, A.3
-
59
-
-
0014723449
-
A rating scale for extrapyramidal side effects
-
Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Stand 1970 Suppl. 212: 11-9
-
(1970)
Acta Psychiatr Stand
, vol.212 SUPPL
, pp. 11-19
-
-
Simpson, G.M.1
Angus, J.W.2
-
60
-
-
0024358369
-
A rating scale for drug-induced akathisia
-
Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6
-
(1989)
Br J Psychiatry
, vol.154
, pp. 672-676
-
-
Barnes, T.R.1
-
61
-
-
0345067539
-
Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol
-
Jun
-
Street J, Tamura R, Sanger T, et al. Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 132
-
(1996)
Eur Neuropsychopharmacol
, vol.6
, Issue.3 SUPPL.
, pp. 132
-
-
Street, J.1
Tamura, R.2
Sanger, T.3
-
62
-
-
8044236531
-
-
Eli Lilly and Company, Indianapolis, USA
-
Olanzapine prescribing information. Eli Lilly and Company, Indianapolis, USA, 1996
-
(1996)
Olanzapine Prescribing Information
-
-
-
63
-
-
0028825096
-
Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents
-
Nov
-
Wagstaff AJ, Bryson HM. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995 Nov; 4 (5): 370-400
-
(1995)
CNS Drugs
, vol.4
, Issue.5
, pp. 370-400
-
-
Wagstaff, A.J.1
Bryson, H.M.2
-
65
-
-
0029132178
-
Measuring the costs of schizophrenia: Implications for the post-institutional era in the US
-
Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia: implications for the post-institutional era in the US. PharmacoEconomics 1945; 8 (3): 199-222
-
(1945)
PharmacoEconomics
, vol.8
, Issue.3
, pp. 199-222
-
-
Terkelsen, K.G.1
Menikoff, A.2
-
66
-
-
84987396796
-
New drugs for the treatment of schizophrenic patients
-
Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta-Psychiatrica-Scandinavica 1995; 91 (388) Suppl.: 24-30
-
(1995)
Acta-Psychiatrica-Scandinavica
, vol.91
, Issue.388 SUPPL.
, pp. 24-30
-
-
Fleischhacker, W.W.1
-
67
-
-
0029902047
-
New antipsychotics
-
Jul
-
Kerwin R, Taylor D. New antipsychotics. Drug Ther 1996 Jul; 6 (1): 71-82
-
(1996)
Drug Ther
, vol.6
, Issue.1
, pp. 71-82
-
-
Kerwin, R.1
Taylor, D.2
-
69
-
-
9544248641
-
Compliance and outcome in patients treated with antipsychotics: The impact of extrapyramidal syndromes
-
Hummer M, Fleischhacker WW. Compliance and outcome in patients treated with antipsychotics: the impact of extrapyramidal syndromes. CNS Drugs 1996; 5 Suppl. 1: 13-20
-
(1996)
CNS Drugs
, vol.5
, Issue.1 SUPPL.
, pp. 13-20
-
-
Hummer, M.1
Fleischhacker, W.W.2
-
71
-
-
0027818640
-
Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties
-
Mar
-
Möller H-J. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 1993 Mar; 3: 1-11
-
(1993)
Eur Neuropsychopharmacol
, vol.3
, pp. 1-11
-
-
Möller, H.-J.1
|